Bibliographie (2530)
Should You Mix and Match Your Booster Shot?
mercredi, 20 octobre 2021 13:44 Écrit par Zouhair SouissiShould You Mix and Match Your Booster Shot? – The Atlantic Related: Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer. A primer on what we know about mixing and matching Covid vaccines. Real-world data […]
The post Should You Mix and Match Your Booster Shot? appeared first on Links Medicus.
RCT: Interferon does not improve outcomes for hospitalized adults with COVID-19.
mercredi, 20 octobre 2021 13:44 Écrit par Zouhair SouissiNews release: Interferon does not improve outcomes for hospitalized adults with COVID-19 – NIH News Releases Original study: Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine
The post RCT: Interferon does not improve outcomes for hospitalized adults with COVID-19. appeared first on Links Medicus.
Long-term consequences of the misuse of ivermectin data.
mardi, 19 octobre 2021 12:55 Écrit par Zouhair SouissiLong-term consequences of the misuse of ivermectin data – The Lancet Infectious Diseases Related: Ivermectin: How false science created a Covid ‘miracle’ drug. Fraudulent ivermectin studies open up new battleground between science and misinformation. The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable. Ivermectin: Cochrane’s most talked about review so far, […]
The post Long-term consequences of the misuse of ivermectin data. appeared first on Links Medicus.
RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.
mardi, 19 octobre 2021 12:55 Écrit par Zouhair SouissiColchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – The Lancet Respiratory Medicine Related: [Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications. COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death […]
The post RECOVERY Trial: In patients admitted to hospital with COVID-19, Colchicine did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death. appeared first on Links Medicus.
Systematic Review: Colchicine for the treatment of COVID‐19 – not beneficial for hospitalized patients; inconclusive evidence for the treatment of non-hospitalized patients, “probably slightly reduces the need for hospitalization or death within 28 days c
mardi, 19 octobre 2021 12:55 Écrit par Zouhair SouissiColchicine for the treatment of COVID‐19 – Cochrane Library Related: [Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications. COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required. [Preprint] RECOVERY […]
The post Systematic Review: Colchicine for the treatment of COVID‐19 – not beneficial for hospitalized patients; inconclusive evidence for the treatment of non-hospitalized patients, “probably slightly reduces the need for hospitalization or death within 28 days compared to placebo”. appeared first on Links Medicus.
What can masks do? Part 2: What makes for a good mask study — and why most fail.
lundi, 18 octobre 2021 05:53 Écrit par Zouhair SouissiCOMMENTARY: What can masks do? Part 2: What makes for a good mask study — and why most fail – CIDRAP See also: COMMENTARY: What can masks do? Part 1: The science behind COVID-19 protection – CIDRAP
The post What can masks do? Part 2: What makes for a good mask study — and why most fail. appeared first on Links Medicus.
J&J COVID-19 Vaccine: FDA recommends booster shot for all adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine.
lundi, 18 octobre 2021 05:53 Écrit par Zouhair SouissiNews release: Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee Commentaries: FDA panel endorses booster shot for J&J COVID-19 vaccine – Associated Press The Johnson & Johnson one-dose vaccine offers good protection now. A booster shot will maximize that, experts say – CNN FDA advisers […]
The post J&J COVID-19 Vaccine: FDA recommends booster shot for all adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine. appeared first on Links Medicus.
![[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.](/media/k2/items/cache/17ac5f8da78c1c03f88e810b46283c98_S.jpg)
[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.
lundi, 18 octobre 2021 05:53 Écrit par Zouhair SouissiBreakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – medRxiv Related: Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high. Cohort study: Pfizer vaccine effectiveness […]
The post [Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”. appeared first on Links Medicus.
RCT supports the use of therapeutic heparin in moderately ill patients admitted to the hospital with Covid-19.
lundi, 18 octobre 2021 05:53 Écrit par Zouhair SouissiEffectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial – The BMJ Commentary: High-dose of readily available blood thinner reduces risk of death for moderately ill COVID-19 patients – St. Michael’s Hospital Related studies (some […]
The post RCT supports the use of therapeutic heparin in moderately ill patients admitted to the hospital with Covid-19. appeared first on Links Medicus.
WHO Report: Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic.
vendredi, 15 octobre 2021 05:50 Écrit par Zouhair SouissiTuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic – World Health Organization Report: Global tuberculosis report 2021 Commentary: Tuberculosis deaths rise for 1st time in years, due to COVID – Associated Press Commentary on Twitter (thread – click for more) ? WHO's Global TB Report […]
The post WHO Report: Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic. appeared first on Links Medicus.
